ABBV
AbbVie Inc.
Latest News for ABBV
In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on AbbVie, with a price target of $222.00. The compan......
With the S&P 500 ($SPX) up 22.8% over the past six months and the Nasdaq ($NDX) surging an even stronger 36.0%, there’s no denying that equities ar......
Analysts have been eager to weigh in on the Healthcare sector with new ratings on AbbVie (ABBV – Research Report) and Merus (MRUS – Research Report......
AbbVie’s ($ABBV) shares weakened on Friday, despite the American drugmaker’s third-quarter fiscal year 2025 earnings surpassing Wall Street’s expec......
In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AbbVie, with a price target of $280.00. The company’s shares opene......
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is currently conducting a Phase 1 clinical study titled ‘A Phase 1, Do......
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A Phase 2, Multicenter, Ran......
Abbvie (($ABBV)) announced an update on their ongoing clinical study. Study Overview: AbbVie is conducting a multicenter, open-label study titled ‘......
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie has completed a Phase 3 clinical study titled ‘A Phase 3 Randomized, P......
News data is sourced from MarketXLS API and updated regularly.
Showing 9 of 9 articles.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABBV | $236.28 | +3.0% | 8.02M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |